These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 305375)

  • 1. Possible mechanisms in the anti-tumour activity of C. parvum.
    Cullen RT
    Dev Biol Stand; 1977 Apr 13-15; 38():265-71. PubMed ID: 305375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of host resistance to Listeria monocytogenes in tumour-bearing mice and the effect of Corynebacterium parvum.
    Miyata H; Himeno K; Miake S; Nomoto K
    Immunology; 1981 Oct; 44(2):305-10. PubMed ID: 7298070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of the potentiation of specific antitumor immunity by intratumor injection of Corynebacterium parvum.
    Miyata H; Himeno K; Nomoto K
    Cancer Res; 1983 Oct; 43(10):4670-5. PubMed ID: 6883325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A role for T lymphocytes in the antitumour action of systemic C. parvum.
    McBride WH; Peters LJ; Mason KA; Milas L
    Dev Biol Stand; 1977 Apr 13-15; 38():253-7. PubMed ID: 305374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophages as effector cells of protective immunity in murine schistosomiasis. VI. T cell-dependent, lymphokine-mediated, activation of macrophages in response to Schistosoma mansoni antigens.
    James SL; Lazdins JK; Hieny S; Natovitz P
    J Immunol; 1983 Sep; 131(3):1481-6. PubMed ID: 6350456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitogenicity of Corynebacterium parvum for mouse lymphocytes.
    Zola H
    Clin Exp Immunol; 1975 Dec; 22(3):514-21. PubMed ID: 817854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditions favouring the selection of either specific or non specific C. parvum-mediated, systemic antitumour immunity in mice.
    Scott MT
    Dev Biol Stand; 1977 Apr 13-15; 38():273-6. PubMed ID: 415921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of resistance to ectromelia virus infection by corynebacterium parvum in murine peritoneal macrophages.
    Cohen DA; Bubel HC
    J Reticuloendothel Soc; 1983 Jan; 33(1):35-46. PubMed ID: 6300395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxical presence of T cell anergy during successful T cell-dependent tumour immunotherapy: characterization of a state of T cell 'amnaesia' following systemic administration of C. parvum.
    McBride WH; Howie S
    Clin Exp Immunol; 1984 Jul; 57(1):139-48. PubMed ID: 6235074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction, maintenance, and reinduction of tumoricidal activity in bone marrow-derived mononuclear phagocytes by Corynebacterium parvum. Evidence for the involvement of a T cell- and interferon-gamma-independent pathway of macrophage activation.
    Keller R; Keist R; Van der Meide PH; Groscurth P; Aguet M; Leist TP
    J Immunol; 1987 Apr; 138(7):2366-71. PubMed ID: 3104463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of thermal response of normal and malignant tissues by Corynebacterium parvum.
    Urano M; Yamashita T; Suit HD; Gerweck LE
    Cancer Res; 1984 Jun; 44(6):2341-7. PubMed ID: 6722772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of different fractions of Corynebacterium parvum on the cytotoxic T-cell response to alloantigens in mice.
    Lichtenstein A; Tuttle R; Cantrell J; Zighelboim J
    J Natl Cancer Inst; 1982 Aug; 69(2):495-501. PubMed ID: 6213807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody responses, antitumour antibodies and Ig class and subclass levels in C. parvum treated mice.
    James K
    Dev Biol Stand; 1977 Apr 13-15; 38():173-81. PubMed ID: 608503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the antitumour activities of glucans and C. parvum.
    Bomford R; Moreno C
    Dev Biol Stand; 1977 Apr 13-15; 38():291-5. PubMed ID: 608513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of in vitro maintenance and interferon-mediated augmentation of natural killer cell activity by adherent peritoneal cells from normal mice.
    Brunda MJ; Taramelli D; Holden HT; Varesio L
    J Immunol; 1983 Apr; 130(4):1974-9. PubMed ID: 6187831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of silica on the anti-tumour activity of "Corynebacterium parvum" (author's transl)].
    Mazurek C; Stiffel C; Chalvet H; Biozzi G
    Ann Immunol (Paris); 1979; 130(6):815-26. PubMed ID: 232975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour growth, phagocytic activity and antibody response in Corynebacterium parvum-treated mice.
    Woodruff MF; McBride WH; Dunbar N
    Clin Exp Immunol; 1974 Jul; 17(3):509-18. PubMed ID: 4549691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of Corynebacterium parvum on the humoral and cellular immune systems in patients with breast cancer.
    Minton JP; Rossio JL; Dixon B; Dodd MC
    Clin Exp Immunol; 1976 Jun; 24(3):441-7. PubMed ID: 1084821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemo-immunotherapy of mouse tumours using cyclophosphamide and C. parvum.
    Scott MT
    Dev Biol Stand; 1977 Apr 13-15; 38():307-10. PubMed ID: 608516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrasting effects of activated and nonactivated macrophages and macrophages from tumor-bearing mice on tumor growth in vivo.
    Gabizon A; Leibovich SJ; Goldman R
    J Natl Cancer Inst; 1980 Nov; 65(5):913-20. PubMed ID: 6933261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.